DSG3 and myasthenia gravis: CAART has been used in autoimmune neurological and dermatological diseases, targeting anti-muscle specific tyrosine kinase (MuSK) and anti-desmoglein 3 (DSG3) autoantibodies, and related clinical trials are ongoing in anti-MuSK antibody positive myasthenia gravis and anti-DSG3 antibody positive mucosal-dominant pemphigus vulgaris (NCT05451212, NCT04422912).